News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
688,423 Results
Type
Article (39425)
Company Profile (306)
Press Release (648692)
Section
Business (204784)
Career Advice (2004)
Deals (35475)
Drug Delivery (87)
Drug Development (80993)
Employer Resources (168)
FDA (16116)
Job Trends (14860)
News (345809)
Policy (32547)
Tag
Academia (2548)
Alliances (49430)
Alzheimer's disease (1234)
Approvals (16047)
Artificial intelligence (130)
Bankruptcy (354)
Best Places to Work (11556)
Biotechnology (217)
Breast cancer (121)
Cancer (1083)
Cardiovascular disease (97)
Career advice (1672)
Cell therapy (234)
Clinical research (64362)
Collaboration (389)
Compensation (197)
COVID-19 (2546)
C-suite (95)
Data (1120)
Diabetes (153)
Diagnostics (6159)
Earnings (84945)
Employer resources (146)
Events (109975)
Executive appointments (310)
FDA (16653)
Funding (352)
Gene therapy (177)
GLP-1 (579)
Government (4339)
Healthcare (18688)
Infectious disease (2631)
Inflammatory bowel disease (110)
Interviews (308)
IPO (16330)
Job creations (3659)
Job search strategy (1429)
Layoffs (417)
Legal (7888)
Lung cancer (170)
Manufacturing (177)
Medical device (13185)
Medtech (13190)
Mergers & acquisitions (19218)
Metabolic disorders (403)
Neuroscience (1511)
NextGen Class of 2024 (6534)
Non-profit (4476)
Northern California (1479)
Obesity (231)
Opinion (183)
Patents (102)
People (56592)
Phase I (20009)
Phase II (28360)
Phase III (21126)
Pipeline (455)
Postmarket research (2554)
Preclinical (8523)
Radiopharmaceuticals (236)
Rare diseases (218)
Real estate (5936)
Regulatory (21583)
Research institute (2315)
Resumes & cover letters (350)
Southern California (1304)
Startups (3614)
United States (13495)
Vaccines (550)
Weight loss (168)
Date
Today (130)
Last 7 days (790)
Last 30 days (3804)
Last 365 days (35747)
2024 (32786)
2023 (40177)
2022 (51287)
2021 (55836)
2020 (54157)
2019 (46644)
2018 (35124)
2017 (32222)
2016 (31629)
2015 (37706)
2014 (31454)
2013 (26499)
2012 (28770)
2011 (29426)
2010 (27525)
Location
Africa (716)
Arizona (192)
Asia (37327)
Australia (6105)
California (3337)
Canada (1287)
China (248)
Colorado (145)
Connecticut (152)
Europe (80001)
Florida (458)
Georgia (116)
Illinois (344)
Indiana (197)
Kansas (97)
Maryland (576)
Massachusetts (2612)
Michigan (157)
Minnesota (272)
New Jersey (952)
New York (958)
North Carolina (702)
Northern California (1479)
Ohio (141)
Pennsylvania (845)
South America (1094)
Southern California (1304)
Texas (464)
Utah (90)
Washington State (361)
688,423 Results for "bridgene biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
BridGene Biosciences Announces Dosing of First Patient in Phase 1 Study Evaluating Novel TEAD Inhibitor BGC515 in Advanced Solid Tumors
BridGene Biosciences, Inc., a leader in developing covalent small molecule drugs for traditional “hard-to-drug” targets, announced today that the first patient has been dosed in its Phase 1 clinical trial of BGC515, a novel TEAD inhibitor discovered through BridGene’s cutting-edge chemoproteomic platform, IMTAC™.
June 28, 2024
·
3 min read
Business
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration and licensing agreement with BridGene Biosciences, Inc. (“Bridgene”), a biotechnology company that uses proprietary chemoproteomics technology to discover novel small molecule drug candidates.
January 3, 2024
·
5 min read
Business
BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets
BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditional “hard-to-drug” targets, announced today a strategic collaboration and licensing agreement with Galapagos NV (Euronext & NASDAQ: GLPG).
January 3, 2024
·
3 min read
Drug Development
BridGene Biosciences Achieves the Second Preclinical Milestone in Takeda Collaboration
BridGene Biosciences, Inc. announced a significant preclinical milestone in its collaboration with Takeda.
August 28, 2023
·
3 min read
Business
BridGene Biosciences Achieves Milestone in Takeda Collaboration
BridGene Biosciences, Inc. announced that it has achieved a significant milestone in its collaboration with Takeda.
March 8, 2023
·
2 min read
Biotech Bay
BridGene Biosciences to Present at Hippo Pathway Targeted Drug Development Summit
BridGene Biosciences, Inc. announced that Wolf Wiedemeyer , Ph.D., head of biology at BridGene, will be giving a presentation, titled “A Covalent TEAD Inhibitor with Exceptional Anti-cancer Activity & Combination Potential,” at the 2nd Annual Hippo Pathway Targeted Drug Development Summit on May 24 in Boston.
May 18, 2023
·
2 min read
Biotech Bay
BridGene Biosciences to Present at Ligase Targeting Drug Development Summit
BridGene Biosciences, Inc. today announced Ping Cao, Ph.D., CEO and co-founder, will give a presentation at the 3rd Annual Ligase Targeting Drug Development Summit on Thursday, April 13, 2023, at 9:00 a.m. ET in Boston, Massachusetts.
April 6, 2023
·
3 min read
Biotech Bay
BridGene Biosciences to Present Pre-Clinical Data of BGI-9004 at the AACR Annual Meeting 2023
BridGene Biosciences, Inc. announced that it will present a poster, titled “Preclinical characterization of BGI-9004, a covalent TEAD inhibitor with exceptional anti-cancer activity and combination potential,” at the American Association for Cancer Research (AACR) Annual Meeting 2023 on April 18 in Orlando.
April 17, 2023
·
2 min read
Biotech Bay
Octave® Bioscience, Inc. Announces Publication in Nature Communications
Octave ® Bioscience, Inc. today announced the publication of a landmark manuscript in the prestigious journal, Nature Communications.
May 29, 2024
·
5 min read
Press Releases
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
November 13, 2024
·
6 min read
1 of 68,843
Next
